Suscribirse

Expectations about treatment of idiopathic pulmonary fibrosis: Comparative survey of patients, carers and physicians (the RESPIR French survey) - 11/06/21

Doi : 10.1016/j.resmer.2020.100811 
V. Cottin a, 1, , E. Bergot b, A. Bourdin c, H. Nunes d, G. Prévot e, B. Wallaert f, S. Marchand-Adam g
a National reference coordinating center for rare lung diseases, pulmonology department, Louis-Pradel hospital, hospices civils de Lyon, UMR754, université de Lyon, université Claude-Bernard Lyon 1, INREA, member of OrphaLung, RespiFil, Radico-ILD, and ERN-LUNG, Lyon, France 
b Pulmonology department, University-affiliated hospital of Caen, Caen, France 
c Pulmonology and addictology department, University-affiliated hospital of Montpellier, Montpellier, France 
d Pulmonology department, AP–HP, Avicenne University Hospital, Bobigny, France 
e Pulmonology department, Hospital of Toulouse, Toulouse, France 
f Pulmonology and Allergy/immunology department, Regional University-affiliated hospital of Lille, Lille, France 
g Pulmonology department, Regional University-affiliated hospital of Tours, Tours, France 

Corresponding author at: Centre national de référence coordonnateur des maladies pulmonaires rares, groupement hospitalier Est, bâtiment A4, pneumologie, 28, avenue Doyen-Lépine, 69677 Lyon cedex, France.Centre national de référence coordonnateur des maladies pulmonaires rares, groupement hospitalier Estbâtiment A4, pneumologie, 28, avenue Doyen-LépineLyon cedex69677France

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

páginas 7
Iconografías 4
Vídeos 0
Otros 0

Abstract

Context

Idiopathic pulmonary fibrosis (IPF) is a severe chronic disease during which anxiety and depression are frequent comorbidities. Better knowledge of patients’ expectations is needed to inform an action plan to improve medical care.

Aim

To describe feelings and expectations of patients suffering from IPF and of their carers about antifibrotic therapy and compare them to what is perceived by their pulmonologist.

Methods

National prospective study on practices and perceptions. Specific questionnaires were e-mailed to all 3276 pulmonologists in France who, in turn, invited patients and carers to participate in a survey.

Results

147 pulmonologists, 161 patients and 144 carers participated in the survey. The role of the carer was evaluated as “important” or “very important” by more than 90% of participants, i.e. pulmonologists, patients or carers. Inconsistencies between how patients felt and how pulmonologists perceived them were identified: 88% of patients responded that they understood quite well what IPF is (vs. 75% of patients according to pulmonologists); 85.5% of patients said they were determined to fight the disease (vs. 68.0%); 61.7% of patients wanted to be kept informed of potential complications before they occurred (vs. 69.6%) and 81.2% wanted to be involved in therapeutic decisions (vs. 43.1%). Globally, patients had a more positive view of antifibrotic therapies than expected by pulmonologists: 41.5% evaluated their advantages superior to what they had expected (vs. 29.1% of patients according to pulmonologists) and 76.5% had a positive image of the benefits/disadvantages ratio (vs. 62.4%). Although pulmonologists had the impression that they were keeping their patients well-informed about exacerbations, hospital stays and the possible negative evolution of the disease despite antifibrotic therapies, 34.0%, 42.0% and 22.0% of patients respectively declared not being aware of these aspects.

Conclusion

The feelings of patients suffering from IPF regarding their disease and treatment globally proved more positive compared with how pulmonologists perceived them. Taking into account the expectations and needs of patients may allow healthcare professionals to better address their needs and priorities.

El texto completo de este artículo está disponible en PDF.

Keywords : Idiopathic pulmonary fibrosis, Patient and carer experience, Survey, Management, Drug therapy


Esquema


© 2021  SPLF and Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 79

Artículo 100811- mai 2021 Regresar al número
Artículo precedente Artículo precedente
  • Prognostic value of lung ultrasound and its link with inflammatory biomarkers in patients with SARS-CoV-2 infection
  • A.L. Wangüemert Pérez, J.M. Figueira Gonçalves, J.M. Hernández Pérez, Y. Ramallo Fariña, J.C. Del Castillo Rodriguez
| Artículo siguiente Artículo siguiente
  • Altitude healing effect in severe asthmatic children
  • P. Quignon, P. da Mata, F. Faraj, S. Guibert, A. Bernard, J. Léonardi, A.D. Loundou, J. Vitte, D. Charpin

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.